Analysis-Launch of arthritis drug biosimilars ramps up US pressure on pricing 'middlemen'
Cheaper versions of one of the most costly and widely used arthritis treatments in the U.S. are likely to fuel further scrutiny of the middlemen that negotiate drug prices for most insured...